TTY Biopharm Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.1yrs
Yönetim Kurulu ortalama görev süresi	8.5yrs

Son yönetim güncellemeleri

Recent updates

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Mar 15

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Feb 25

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Feb 07

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

Jan 19

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 10

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Nov 25

CEO

TTY Biopharm CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kuo-Chiang Chang	Chief Financial Officer	less than a year	Veri yok	Veri yok
Shu-Wen Wang	Accounting Officer	9.3yrs	Veri yok	Veri yok
Shu-Fen Huang	Chief Legal & Compliance Officer	2.7yrs	Veri yok	Veri yok
Wei-Ying Yin	Director of Public Affairs Department	no data	Veri yok	Veri yok
Jen-Yang Chang	Chief Human Resource Officer	5.6yrs	Veri yok	Veri yok
Si-Yuan Yang	Senior Vice President	15.6yrs	Veri yok	Veri yok
Allen Chu	Head of Intensive Care Business Unit	no data	Veri yok	Veri yok
Ching-Lan Hou	General Manager	2.7yrs	Veri yok	Veri yok
Yung-Min Chiang	Chief Auditor	no data	Veri yok	Veri yok

4.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 4105 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tze-Kaing Yang	Director	8.5yrs	Veri yok	Veri yok
Chuan-Quan Lin	Chairman of the Board	13.5yrs	Veri yok	0.084% NT$ 15.3m
Ming-Ling Hsueh	Independent Director	8.5yrs	Veri yok	Veri yok
Wen-Hwa Chang	Vice Chairman	29.4yrs	Veri yok	7.56% NT$ 1.4b
Ying-Ying Liao	Director	8.5yrs	Veri yok	Veri yok
Carl Hsiao	Representative Director	5.8yrs	Veri yok	0.35% NT$ 64.1m
Ming-Dao Chang	Independent Director	less than a year	Veri yok	Veri yok
An-Li Zheng	Independent Director	less than a year	Veri yok	Veri yok
Shi-Chang Xu	Representative Director	less than a year	Veri yok	Veri yok

8.5yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4105 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/22 14:11
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

TTY Biopharm Company Limited 11 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yenya Kuo	Capital Securities Corporation
Jerry Su	Credit Suisse
Christine Wang	Daiwa Securities Co. Ltd.

TTY Biopharm Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

TTY Biopharm Company Limited Announces Change of CFO and Financial Officer

TTY Biopharm Company Limited, Annual General Meeting, May 30, 2024

Less than half of directors are independent

TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022

Less than half of directors are independent

TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee

Recent updates

Third quarter 2024 earnings released: EPS: NT$1.50 (vs NT$1.51 in 3Q 2023)

TTY Biopharm Company Limited to Report Q3, 2024 Results on Nov 13, 2024

Second quarter 2024 earnings released: EPS: NT$1.05 (vs NT$1.24 in 2Q 2023)

TTY Biopharm Company Limited to Report Q2, 2024 Results on Aug 08, 2024

Now 20% undervalued after recent price drop

TTY Biopharm Company Limited Approves Cash Dividend for the Year 2023

Price target decreased by 9.3% to NT$78.00

Now 20% undervalued after recent price drop

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

TTY Biopharm Company Limited to Report Q1, 2024 Results on May 07, 2024

Upcoming dividend of NT$3.50 per share

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Dividend increased to NT$3.50

TTY Biopharm Company Limited Announces Change of CFO and Financial Officer

TTY Biopharm Company Limited, Annual General Meeting, May 30, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 10% to NT$86.00

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to NT$84.50

TTY Biopharm Company Limited Announces Decision Rendered by the Supreme Court for Validity of the Risperidone Development Agreement Between the Company and Center Laboratories, Inc

Now 20% undervalued after recent price drop

Upcoming dividend of NT$3.40 per share at 4.3% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to NT$71.50

Price target increased to NT$79.50

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$3.00 per share

TTY Biopharm Company Limited Announces Dividend Distribution, Payable on August 15, 2022

TTY Biopharm Company Limited Announces Cash Dividend for the Year 2021

Price target decreased to NT$73.00

Less than half of directors are independent

TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee

Price target decreased to NT$73.67

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Third quarter 2021 earnings released: EPS NT$1.02 (vs NT$0.90 in 3Q 2020)

Upcoming dividend of NT$4.00 per share

Price target increased to NT$80.00

Consensus EPS estimates fall to NT$2.87

Second quarter 2021 earnings released: EPS NT$0.13 (vs NT$0.75 in 2Q 2020)

Price target increased to NT$80.20

Price target increased to NT$80.20

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$0.82 (vs NT$1.02 in 1Q 2020)

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Tty Biopharm Company Limited Proposes Dividend for the Period January 1, 2020 to December 31, 2020

Full year 2020 earnings released: EPS NT$3.72 (vs NT$3.62 in FY 2019)

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

PAION AG Enters into License Agreement with TTY Biopharm Company Limited

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Price target lowered to NT$73.50

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

TTY Biopharm Company Limited, Annual General Meeting, Jun 09, 2021

New 90-day low: NT$61.40

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

New 90-day low: NT$68.10

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

TTY Biopharm Company Limited Announces Executive Changes, with Effect from January 20, 2021

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS NT$0.89

Market bids up stock over the past week

New 90-day high: NT$84.30

Analysts lower revenue estimates to NT$4.14b